The role of macrophages in the development of human renal allograft fibrosis in the first year after transplantation

American Journal of Transplantation

Volumn 14, Issue 9, 2014, Pages 2126-2136

  Toki, D ^a   Zhang, W ^b   Hor, K L M ^a   Liuwantara, D ^a   Alexander, S I ^a   Yi, Z ^b   Sharma, R ^c   Chapman, J R ^a   Nankivell, B J ^a   Murphy, B ^b   O'Connell, P J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

Clinical research practice; fibrosis; genomics; immunobiology; kidney (allograft) function dysfunction; kidney transplantation nephrology; macrophage monocyte biology; pathology histopathology; translational research science

Indexed keywords

CD206 PROTEIN; CELL PROTEIN; CHLORDANE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; UNCLASSIFIED DRUG;

ADULT; ALLOIMMUNITY; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FIBROSING ALVEOLITIS; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATORY INFILTRATE; KIDNEY ALLOGRAFT FIBROSIS; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MICROARRAY ANALYSIS; PHENOTYPE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; STAINING; UPREGULATION; FIBROSIS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; FEMALE; FIBROSIS; HUMANS; KIDNEY TRANSPLANTATION; MACROPHAGES; MALE; MIDDLE AGED;

EID: 84906218306     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12803     Document Type: Article

References (36)

1. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR., The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
2. Chapman JR, O'Connell PJ, Nankivell BJ., Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015-3026.
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD., Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 2004; 78: 434-441.
4. Nankivell BJ, Chapman JR., Chronic allograft nephropathy: Current concepts and future directions. Transplantation 2006; 81: 643-654.
5. Vongwiwatana A, Tasanarong A, Rayner DC, Melk A, Halloran PF., Epithelial to mesenchymal transition during late deterioration of human kidney transplants: The role of tubular cells in fibrogenesis. Am J Transplant 2005; 5: 1367-1374.
6. Rodder S, Scherer A, Raulf F, et al. Renal allografts with IF/TA display distinct expression profiles of metzincins and related genes. Am J Transplant 2009; 9: 517-526.
7. Vitalone MJ, O'Connell PJ, Jimenez-Vera E, et al. Epithelial-to- mesenchymal transition in early transplant tubulointerstitial damage. J Am Soc Nephrol 2008; 19: 1571-1583.
8. Humphreys BD, Lin SL, Kobayashi A, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010; 176: 85-97.
9. LeBleu VS, Taduri G, O'Connell J, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 2013; 19: 1047-1053.
10. Grimm PC, Nickerson P, Jeffery J, et al. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med 2001; 345: 93-97.
11. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR., Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78: 242-249.
12. Wynn TA., Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210.
13. Wynn TA., Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011; 208: 1339-1350.
14. Murray PJ, Wynn TA., Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11: 723-737.
15. Tinckam KJ, Djurdjev O, Magil AB., Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. Kidney Int 2005; 68: 1866-1874.
16. Papadimitriou JC, Drachenberg CB, Munivenkatappa R, et al. Glomerular inflammation in renal allografts biopsies after the first year: Cell types and relationship with antibody-mediated rejection and graft outcome. Transplantation 2010; 90: 1478-1485.
17. Grimm PC, McKenna R, Nickerson P, et al. Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J Am Soc Nephrol 1999; 10: 1582-1589.
18. Girlanda R, Kleiner DE, Duan Z, et al. Monocyte infiltration and kidney allograft dysfunction during acute rejection. Am J Transplant 2008; 8: 600-607.
19. Pilmore HL, Painter DM, Bishop GA, McCaughan GW, Eris JM., Early up-regulation of macrophages and myofibroblasts: A new marker for development of chronic renal allograft rejection. Transplantation 2000; 69: 2658-2662.
20. Vitalone MJ, O'Connell PJ, Wavamunno M, Fung CL, Chapman JR, Nankivell BJ., Transcriptome changes of chronic tubulointerstitial damage in early kidney transplantation. Transplantation 2010; 89: 537-547.
21. Moreso F, Seron D, O'Valle F, et al. Immunephenotype of glomerular and interstitial infiltrating cells in protocol renal allograft biopsies and histological diagnosis. Am J Transplant 2007; 7: 2739-2747.
22. Mengel M, Reeve J, Bunnag S, et al. Molecular correlates of scarring in kidney transplants: The emergence of mast cell transcripts. Am J Transplant 2009; 9: 169-178.
23. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
24. Mosser DM, Edwards JP., Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969.
25. Etzerodt A, Moestrup SK., CD163 and inflammation: Biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal 2013; 18: 2352-2363.
26. Park WD, Griffin MD, Cornell LD, Cosio FG, Stegall MD., Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21: 1987-1997.
27. Barron L, Wynn TA., Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol 2011; 300: G723-G728.
28. Nagaoka I, Trapnell BC, Crystal RG., Upregulation of platelet-derived growth factor-A and -B gene expression in alveolar macrophages of individuals with idiopathic pulmonary fibrosis. J Clin Invest 1990; 85: 2023-2027.
29. Madala SK, Pesce JT, Ramalingam TR, et al. Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis. J Immunol 2010; 184: 3955-3963.
30. Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56-65.
31. Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001; 194: 809-821.
32. Porcheray F, Viaud S, Rimaniol AC, et al. Macrophage activation switching: An asset for the resolution of inflammation. Clin Exp Immunol 2005; 142: 481-489.
33. Romagnani P, Lazzeri E, Lasagni L, et al. IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. J Am Soc Nephrol 2002; 13: 53-64.
34. El Fiky A, Perreault R, McGinnis GJ, Rabin RL., Attenuated expression of interferon-beta and interferon-lambda1 by human alternatively activated macrophages. Hum Immunol 2013; 74: 1524-1530.
35. Fuentes-Duculan J, Suarez-Farinas M, Zaba LC, et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol 2010; 130: 2412-2422.
36. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J., Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005; 175: 342-349.